Skip to main
DOCS
DOCS logo

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 39%
Sell 6%
Strong Sell 6%

Bulls say

Doximity Inc. demonstrated robust growth in its point-of-care (POC) and formulary offerings, with an impressive increase of over 100% during the recent buying season, underscoring strong demand for its services among medical professionals. Since the release of the recent Memorandum, Doximity's shares have experienced a modest uptick of 3.2%, indicating improved investor sentiment and market confidence in the company's growth trajectory. Additionally, the guidance for the second quarter shows achievable targets, with the potential for upside growth, reinforcing a positive outlook for the company's future performance.

Bears say

Doximity Inc. is facing a negative outlook due to downward guidance revisions from its pharmaceutical clients for fiscal years 2023 and 2024, attributed to an uncertain economic environment. Additionally, the company's stock is considered expensive when compared to its software peers, which may lead to increased volatility if financial results do not meet high investor expectations. The potential for disappointment exists, particularly if Doximity fails to deliver positive outcomes or raise guidance in response to heightened scrutiny on its financial performance.

Doximity (DOCS) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 18 analysts, Doximity (DOCS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.